Lv7
4680 积分 2023-12-10 加入
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
7天前
已完结
Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020
7天前
已完结
177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
7天前
已完结
Prostate cancer
7天前
已完结
Advances in diagnosis and treatment of testicular cancer
1个月前
已完结
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
1个月前
已完结
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review
4个月前
已完结
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches
4个月前
已关闭
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer
6个月前
已完结
Mechanisms of mitophagy in cellular homeostasis, physiology and pathology
7个月前
已完结
Evaluation of the new control methods for oral poliomyelitis vaccine
皖公网安备34019202002308
